title: Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.
abstract: This article summarizes the importance of different targets such as 5α-reductase, 17β-HSD, CYP17A, androgen receptor and protein kinase A for the treatment of prostate cancer and benign prostatic hyperplasia. It is a well known fact that dihydrotestosterone (DHT) is associated with the development of androgen-dependent afflictions. At the present time, several research groups are attempting to develop new steroidal and non-steroidal molecules with the purpose of inhibiting the synthesis and biological response of DHT. This review also discusses the most recent studies reported in the literature that describe the therapeutic potential of novel compounds, as well as the new drugs, principally inhibitors of 5α-reductase.
authors: Departamento De Sistemas Biológicos, Universidad Autónoma Metropolitana- Xochimilco Calzada Del Hueso No. 1100, México, D.F., C.P. 04960, México. marisa@correo.xoc.uam.mx.
authors: Marisa
authors: M
authors: Cabeza
authors: Araceli
authors: A
authors: Sánchez-Márquez
authors: Mariana
authors: M
authors: Garrido
authors: Aylín
authors: A
authors: Silva
authors: Eugene
authors: E
authors: Bratoeff
mesh_terms: D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000378:metabolism; D058891:5-alpha Reductase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D000728:Androgens / Q000378:metabolism*; D013196:Dihydrotestosterone / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D055808:Drug Discovery; D006801:Humans; D008297:Male; D008968:Molecular Conformation; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism*; D013329:Structure-Activity Relationship
chemical_list: D058891:5-alpha Reductase Inhibitors; D000728:Androgens; D013196:Dihydrotestosterone; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase